News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial featuring patient-tailored microperimetry for geographic atrophy studies at EURETINA 2026 -
-
-
-